J&J PAYING $181M TO SETTLE CLAIMS OVER RISPERDAL MEDICATION ADS

 

A Johnson & Johnson subsidiary agreed Thursday to pay $181 million to settle dozens of states' claims that it engaged in illegal off-label marketing of antipsychotic drugs, with New Jersey to receive $5.3 million. Janssen Pharmaceuticals Inc. of Titusville improperly marketed Risperdal, Risperdal Consta, Risperdal M-Tab and Invega, in violation of federal law, according to Chiesa v. Janssen Pharmaceuticals, MER-C-75-12. The drugs are primarily used to treat schizophrenia and bipolar mania, but have off-label uses. While doctors also may prescribe Risperdal to treat Alzheimer's disease, dementia, depression and other disorders, the Food and Drug Administration has not approved it for those uses.

 

Top